Save
Identifying novel molecular differences between WHO grade I and II meningiomas
EANS Academy. Sofela A. 09/26/19; 275937; EP04022
Mr. Agbolahan Sofela
Mr. Agbolahan Sofela

Access to this content is reserved for EANS members and attendees of this event. Click here to become an EANS member and gain your access to the full content of the EANS Academy


Abstract
Discussion Forum (0)
Rate & Comment (0)
Background: With the increasing emphasis on the integrated histo-pheno-genotypical diagnoses of central nervous system (CNS) tumours, there is an unmet need for the identification of biomarkers to aid in the diagnosis, clinical management, prognosis and follow-up of meningiomas. WHO grade II meningiomas remain a controversial group of CNS tumours to diagnose and treat, compared to the more prevalent and extensively researched grade I tumours.
Aim: To identify molecular signatures (biomarkers) unique to grade II meningiomas (versus grade I) and describe their potential use in clinical practice.
Methods: Unbiased global proteomic analyses of four grade I and four grade II primary (meningioma) cell-cultures were carried out to identify proteins differentially expressed between both grades.
Differential expression and statistical analyses were performed using Perseus and Microsoft Excel.
The significantly-differentially expressed proteins were validated by Western blot, IHC and ELISA, using tumour tissue and primary cells.
Results: We identified 3557 proteins commonly expressed in both meningioma grades. Further analysis revealed that 85 of these were significantly-differentially up/down-regulated.
Initial validation studies on some of the promising candidates have confirmed the patterns of expression between the two tumour grades.
Conclusion: The findings of this study have identified novel biomolecular differences between grade I/II meningiomas that can potentially aid in the diagnosis and clinical management of grade II meningiomas. Further validation studies and functional assays are being carried out to better understand the role these promising candidates play in the biology of grade II meningiomas.
Background: With the increasing emphasis on the integrated histo-pheno-genotypical diagnoses of central nervous system (CNS) tumours, there is an unmet need for the identification of biomarkers to aid in the diagnosis, clinical management, prognosis and follow-up of meningiomas. WHO grade II meningiomas remain a controversial group of CNS tumours to diagnose and treat, compared to the more prevalent and extensively researched grade I tumours.
Aim: To identify molecular signatures (biomarkers) unique to grade II meningiomas (versus grade I) and describe their potential use in clinical practice.
Methods: Unbiased global proteomic analyses of four grade I and four grade II primary (meningioma) cell-cultures were carried out to identify proteins differentially expressed between both grades.
Differential expression and statistical analyses were performed using Perseus and Microsoft Excel.
The significantly-differentially expressed proteins were validated by Western blot, IHC and ELISA, using tumour tissue and primary cells.
Results: We identified 3557 proteins commonly expressed in both meningioma grades. Further analysis revealed that 85 of these were significantly-differentially up/down-regulated.
Initial validation studies on some of the promising candidates have confirmed the patterns of expression between the two tumour grades.
Conclusion: The findings of this study have identified novel biomolecular differences between grade I/II meningiomas that can potentially aid in the diagnosis and clinical management of grade II meningiomas. Further validation studies and functional assays are being carried out to better understand the role these promising candidates play in the biology of grade II meningiomas.
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings